Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Cerilliant
Farmers Insurance
Chubb
Moodys
Healthtrust
Covington
Citi
Julphar
Chinese Patent Office

Generated: August 23, 2017

DrugPatentWatch Database Preview

ADALAT CC Drug Profile

« Back to Dashboard

What is the patent landscape for Adalat Cc, and what generic Adalat Cc alternatives are available?

Adalat Cc is a drug marketed by Alvogen and is included in one NDA.

The generic ingredient in ADALAT CC is nifedipine. There are thirty-nine drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

Summary for Tradename: ADALAT CC

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Bulk Api Vendors: see list90
Clinical Trials: see list20
Patent Applications: see list7,030
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADALAT CC at DailyMed

Pharmacology for Tradename: ADALAT CC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993AB1RXYesNo► Subscribe► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-002Apr 21, 1993AB1RXYesYes► Subscribe► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993AB1RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ADALAT CC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-002Apr 21, 1993► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-002Apr 21, 1993► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Teva
Medtronic
US Army
Federal Trade Commission
Citi
McKinsey
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot